查找临床试验
已按「免疫性血小板减少症」检索，对应国际通用词 immune thrombocytopenia
共找到 59 项正在招募的试验（在中国／港澳台设有中心）
数据更新于 23:04，每 5 分钟自动同步BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
China
年龄 18 Years – 65 Years
Peking University People's Hospital
The Efficacy and Safety of Combined Teriflunomide and High-dose Dexamethasone in Newly Diagnosed Primary Immune Thrombocytopenia (TEMPO-2)
China
年龄 18 Years – 不限
Peking University People's Hospital
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases
China
年龄 18 Years – 不限
Institute of Hematology & Blood Diseases Hospital, China
Anti-CD38 Antibody Treating Pediatric Primary Immune Thrombocytopenia (ITP)
China
年龄 6 Years – 17 Years
Institute of Hematology & Blood Diseases Hospital, China
The Efficacy and Safety of HCQ Plus TPO-RA in ANA Positive ITP
China、Hong Kong、Macau
年龄 15 Years – 99 Years
Yunfeng Cheng
Safety Study of CC312 in Autoimmune Disease Patients
China
年龄 18 Years – 不限
CytoCares Inc
Anti-CD38 Antibody Treating Elderly Patients With Primary Immune Thrombocytopenia (ITP)
China
年龄 60 Years – 不限
Institute of Hematology & Blood Diseases Hospital, China
Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS
Brazil、China、Czechia、India、Japan 等 6 国
年龄 18 Years – 100 Years
Novartis Pharmaceuticals
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
United States、Australia、Bulgaria、China、Croatia 等 12 国
年龄 18 Years – 不限
Takeda
A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia (ITP)
China
年龄 12 Years – 18 Years
Institute of Hematology & Blood Diseases Hospital, China
A Dose-escalation Study Followed by a Dose Optimal Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia
China
年龄 18 Years – 65 Years
CASI pharmaceuticals, Inc.
High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune Thrombocytopenia
China
年龄 18 Years – 80 Years
Shandong University